Search - tctmd.com

Displaying 341 - 360 of 2022

Sort: Relevancy | Date

Presentation THT 2025

Cardiac Recovery in Cardiogenic Shock Patients Treated With Impella 5.5

Presenter: Alexis Barnes

February 11, 2025

Presentation THT 2025

TRISCEND II Trial: Right Heart Failure Outcomes in Patients With Severe Tricuspid Regurgitation at One Year

Presenter: Aasim Afzal

February 11, 2025

Presentation THT 2025

Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Use in Cardiac Sarcoidosis Cardiomyopathy

Presenter: Ahmed Mahmoud

February 11, 2025

Presentation THT 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Clinical Characteristics and Predictors of Mortality in Cardiogenic Shock: A PREMIER Healthcare Database Analysis

Presenter: Joseph Ibrahim

February 11, 2025

Presentation THT 2025

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

Presenter: Arvind Kumar Venkataramana Raju

February 11, 2025

Presentation THT 2025

Acute Hemodynamic Effects of Impella 5.5 in Cardiogenic Shock and Decompensated Heart Failure on Hepatorenal Function

Presenter: Gabrielle Daso

February 11, 2025

Presentation THT 2025

Use of Vericiguat in Durable Left Ventricular Assist Device Patients

Presenter: Boaz Elad

February 11, 2025

Presentation THT 2025

Efficacy of Silverlon Silver Plated Dressing Pad in Reducing Left Ventricular Assist Device Driveline Infections When Compared to Chlorhexidine Impregnated Disc

Presenter: John DePietro

February 11, 2025

Presentation THT 2025

Trends and Outcomes of Revascularization in Cardiogenic Shock: A Matched Cohort Analysis

Presenter: Joseph Ibrahim

February 11, 2025

Presentation THT 2025

Sex Differences in the Utilization and Outcomes of Advanced MCS Devices in Cardiogenic Shock

Presenter: Emily Rodriguez

February 11, 2025

Presentation THT 2025

Flow Restoration Leads to LV Mass Regression After DurAVR® Biomimetic THV Implant: MRI Study

Presenter: Christopher Meduri

February 11, 2025

Presentation THT 2025

Impact of Obesity on Clinical Outcomes of Cardiogenic Shock Patients Treated With Advanced Mechanical Circulatory Support

Presenter: Abduljabar Adi

February 11, 2025

Presentation THT 2025

Mechanical Circulatory Support Within a Large Academic Health System

Presenter: Arinze Bosah

February 11, 2025

Presentation THT 2025

Heart Failure Management Using a Risk Score From an Insertable Cardiac Monitor: The Rationale and Design of the ALLEVIATE-HF Trial

Presenter: Javed Butler

February 11, 2025

Presentation THT 2025

Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Subcutaneous (SC) Injection of a Novel-Formulation of Furosemide (FUR) Administered via an Autoinjector

Presenter: John Mohr

February 11, 2025

Presentation THT 2025

Management of Clinically Stable Patients With Impella 5.5 on a Cardiac Stepdown Unit Is Associated With Low Adverse Event Rates and Lower Hospital Costs

Presenter: Anthony Carnicelli

February 11, 2025

Presentation THT 2025

Effect of Vericiguat on Pulmonary Artery Pressures in Heart Failure Patients: Insights From Pressure Sensor Monitoring

Presenter: Boaz Elad

February 11, 2025

Presentation THT 2025

Relationship Between Changes in Pulmonary Artery Pressure, Blood Pressure and Weight in Response to Titration of Heart Failure Medications During Ambulatory Monitoring

Presenter: Sandip Zalawadiya

February 11, 2025

Presentation THT 2025

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Presenter: Dmitry Yaranov

February 11, 2025

Advertisement

Cardiac Recovery in Cardiogenic Shock Patients Treated With Impella 5.5

TRISCEND II Trial: Right Heart Failure Outcomes in Patients With Severe Tricuspid Regurgitation at One Year

Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Use in Cardiac Sarcoidosis Cardiomyopathy

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Clinical Characteristics and Predictors of Mortality in Cardiogenic Shock: A PREMIER Healthcare Database Analysis

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

Acute Hemodynamic Effects of Impella 5.5 in Cardiogenic Shock and Decompensated Heart Failure on Hepatorenal Function

Use of Vericiguat in Durable Left Ventricular Assist Device Patients

Efficacy of Silverlon Silver Plated Dressing Pad in Reducing Left Ventricular Assist Device Driveline Infections When Compared to Chlorhexidine Impregnated Disc

Trends and Outcomes of Revascularization in Cardiogenic Shock: A Matched Cohort Analysis

Sex Differences in the Utilization and Outcomes of Advanced MCS Devices in Cardiogenic Shock

Flow Restoration Leads to LV Mass Regression After DurAVR® Biomimetic THV Implant: MRI Study

Impact of Obesity on Clinical Outcomes of Cardiogenic Shock Patients Treated With Advanced Mechanical Circulatory Support

Mechanical Circulatory Support Within a Large Academic Health System

Heart Failure Management Using a Risk Score From an Insertable Cardiac Monitor: The Rationale and Design of the ALLEVIATE-HF Trial

Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Subcutaneous (SC) Injection of a Novel-Formulation of Furosemide (FUR) Administered via an Autoinjector

Management of Clinically Stable Patients With Impella 5.5 on a Cardiac Stepdown Unit Is Associated With Low Adverse Event Rates and Lower Hospital Costs

Effect of Vericiguat on Pulmonary Artery Pressures in Heart Failure Patients: Insights From Pressure Sensor Monitoring

Relationship Between Changes in Pulmonary Artery Pressure, Blood Pressure and Weight in Response to Titration of Heart Failure Medications During Ambulatory Monitoring

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content